Dr. Wu Xiangsong (吴向崧) — Advanced Gallbladder Cancer Conversion Therapy & Minimally Invasive Surgery | Xinhua Hospital Shanghai
For patients with advanced gallbladder cancer who have been told that surgery is not possible, Dr. Wu Xiangsong (吴向崧) at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, offers a message of genuine hope grounded in clinical evidence: with the right conversion therapy strategy, a significant proportion of patients initially deemed inoperable can be brought to curative-intent surgery. As one of China's earliest and most experienced practitioners of conversion therapy for advanced gallbladder cancer, Dr. Wu has achieved radical resection rates exceeding 60% in patients who presented with locally advanced or borderline resectable disease — a result that places him among the most accomplished gallbladder cancer surgeons in the country.
Specialty Focus
- Advanced gallbladder cancer: conversion therapy and radical surgical resection
- Gallbladder cancer at all stages: surgical planning, resection, and comprehensive treatment
- Cholangiocarcinoma: intrahepatic, hilar, and distal
- Pancreatic cancer: surgical resection including Whipple procedure
- Hepatocellular carcinoma: surgical resection and minimally invasive approaches
- Robotic surgery for hepatobiliary-pancreatic malignancies
- Laparoscopic minimally invasive hepatobiliary surgery
Academic & Clinical Titles
- Chief Physician (主任医师), Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Deputy Administrative Director, Department of General Surgery, Xinhua Hospital
- One of China's earliest practitioners of conversion therapy for advanced gallbladder cancer
- Radical resection rate exceeding 60% following conversion therapy in advanced gallbladder cancer patients
Conversion Therapy: Turning "Inoperable" Into Operable
The concept of conversion therapy — using systemic treatment to downstage a tumor that is initially unresectable, with the goal of enabling subsequent curative-intent surgery — has transformed outcomes in several gastrointestinal cancers, most notably colorectal cancer with liver metastases and gastric cancer. In gallbladder cancer, the application of this concept is more recent and technically more demanding, but the potential benefit is enormous: gallbladder cancer has a very poor prognosis when treated with systemic therapy alone, but patients who achieve R0 surgical resection have significantly better long-term outcomes.
Dr. Wu Xiangsong is one of the pioneers of this approach in China. His clinical program for advanced gallbladder cancer conversion therapy involves:
1. Careful patient selection: Not all advanced gallbladder cancer patients are candidates for conversion therapy. The key question is whether the tumor's pattern of spread — local extension to adjacent structures, vascular involvement, regional lymph node metastases — is potentially addressable by surgery if the tumor responds to systemic treatment. Dr. Wu's experience allows him to identify patients with genuine conversion potential from those for whom surgery is unlikely to become feasible regardless of treatment response.
2. Optimized systemic therapy: The choice of conversion regimen is critical. Standard gemcitabine + cisplatin chemotherapy, newer combinations incorporating nab-paclitaxel or S-1, and increasingly, molecularly targeted agents (for patients with FGFR2 fusions, IDH1 mutations, HER2 amplification, or other actionable alterations) are all potential components of a conversion strategy. Dr. Wu's team integrates molecular profiling into the treatment planning process to identify patients who may benefit from targeted agents as part of their conversion regimen.
3. Response assessment and surgical timing: Determining the optimal moment to proceed to surgery — when the tumor has responded sufficiently to enable R0 resection but before the patient develops treatment-related toxicity or disease progression — requires experienced judgment. Dr. Wu's extensive experience with this decision point is a key component of his program's success.
4. Complex surgical resection: Conversion surgery for advanced gallbladder cancer is technically demanding, often requiring extended hepatectomy, bile duct resection with reconstruction, portal vein resection, and regional lymphadenectomy. Dr. Wu's surgical expertise — including his proficiency with robotic and laparoscopic approaches — enables him to perform these complex resections with the precision required to achieve clear margins.
The result: a radical resection rate exceeding 60% in patients who presented with advanced, initially inoperable gallbladder cancer. For patients who have been told surgery is not possible, this figure represents a meaningful probability of achieving the only treatment with curative potential.
Robotic & Laparoscopic Surgery: Precision Minimally Invasive Hepatobiliary Surgery
Beyond his conversion therapy expertise, Dr. Wu Xiangsong is a specialist in robotic and laparoscopic minimally invasive surgery for hepatobiliary-pancreatic malignancies. Minimally invasive approaches to liver, bile duct, and pancreatic surgery offer potential advantages including reduced blood loss, shorter hospital stay, faster recovery, and lower rates of wound complications — benefits that are particularly meaningful for patients who have already undergone systemic therapy and may have compromised physiological reserve.
Robotic surgery, in particular, offers enhanced visualization and instrument precision for complex biliary reconstructions and vascular dissections — the technically demanding steps that are central to gallbladder cancer and cholangiocarcinoma surgery. Dr. Wu's proficiency with robotic platforms allows him to apply minimally invasive techniques to cases that would require open surgery at centers without this expertise.
Xinhua Hospital: A Major Shanghai Academic Medical Center
Xinhua Hospital is one of Shanghai's leading academic medical centers, affiliated with Shanghai Jiao Tong University School of Medicine — China's top-ranked medical school. The hospital's Department of General Surgery, where Dr. Wu serves as Deputy Administrative Director, has comprehensive capabilities in hepatobiliary-pancreatic surgery, supported by advanced imaging, interventional radiology, medical oncology, and radiation oncology services.
For international patients, Xinhua Hospital's infrastructure — including its robotic surgery program, advanced pathology and molecular diagnostics, and multidisciplinary tumor board — provides the institutional support needed for complex biliary tract cancer management.
Who Should Consider Consulting Dr. Wu Xiangsong
- Patients with advanced or locally advanced gallbladder cancer who have been told surgery is not possible
- Patients with gallbladder cancer who want a second surgical opinion on resectability
- Patients currently receiving systemic therapy for gallbladder cancer who want to explore conversion surgery potential
- Patients with cholangiocarcinoma (intrahepatic, hilar, or distal) seeking surgical evaluation
- Patients with hepatobiliary-pancreatic malignancies who prefer minimally invasive (robotic or laparoscopic) surgical approaches
- Patients with pancreatic cancer requiring complex surgical resection
What to Prepare Before Your Consultation
- CT abdomen/pelvis with contrast (biliary protocol preferred) — most recent, ideally within 4–6 weeks
- MRI/MRCP if available — particularly valuable for biliary anatomy assessment
- PET-CT if available — for distant metastasis assessment
- Pathology report with histological type and grade
- Molecular profiling (NGS panel) if available — FGFR2, IDH1, HER2, BRAF, MSI status
- Tumor markers: CA 19-9, CEA, AFP (most recent and serial values)
- Liver function tests and complete blood count
- Prior treatment summary: all systemic therapy received, response assessments, and reasons for any treatment changes
How CMCS Connects You with Dr. Wu Xiangsong
China Medical Concierge Shanghai (CMCS) facilitates access to Dr. Wu Xiangsong for international patients with advanced gallbladder cancer, cholangiocarcinoma, and related hepatobiliary malignancies. Our team manages the full coordination process — from remote resectability assessment and medical record translation to appointment scheduling, interpretation, and in-hospital support.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation resectability and conversion therapy eligibility assessment
- Appointment coordination with Dr. Wu Xiangsong's clinic at Xinhua Hospital
- On-site interpretation during consultations and procedures
- Molecular profiling coordination for targeted therapy eligibility
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Dr. Wu Xiangsong
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comentarios